AbbVie Inc. $ABBV Stock Sold by Cardinal Capital Management Inc.

Cardinal Capital Management Inc. lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 10.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 245,195 shares of the company’s stock after selling 28,524 shares during the period. AbbVie makes up 1.5% of Cardinal Capital Management Inc.’s investment portfolio, making the stock its 21st largest position. Cardinal Capital Management Inc.’s holdings in AbbVie were worth $64,141,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ABBV. State Street Corp raised its holdings in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after buying an additional 1,379,232 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new position in AbbVie during the second quarter worth about $2,905,952,000. Deutsche Bank AG boosted its stake in AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares during the period. Finally, Amundi increased its position in shares of AbbVie by 2.4% during the first quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after acquiring an additional 247,689 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

AbbVie Price Performance

Shares of AbbVie stock opened at $285.32 on Friday. The stock has a market capitalization of $504.10 billion, a price-to-earnings ratio of 80.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. The business has a 50-day moving average of $262.74 and a 200 day moving average of $239.22. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $291.40.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Analyst Ratings Changes

ABBV has been the topic of a number of research analyst reports. HSBC boosted their price target on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Scotiabank increased their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. BNP Paribas Exane lifted their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Finally, Leerink Partners boosted their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $277.18.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.